PharmaEssentia has announced a blockbuster fiscal year for 2025, reaching all-time highs across all key financial metrics. The company reported consolidated revenue of NT$15.64 billion, with a gross profit of NT$13.95 billion and a sector-leading gross margin of 89%. Net income attributable to the parent company reached NT$5.05 billion, resulting in a record EPS of $13.64.

The Board of Directors has approved a total dividend of NT$2.6 per share (comprising $1.5 in cash and $1.1 in stock), marking a new milestone for shareholder returns.

• Growth Drivers: The primary catalyst remains Ropeg (Ropeginterferon alfa-2b), a proprietary long-acting interferon approved in nearly 50 countries for Polycythemia Vera (PV), including the US, Japan, China, and the EU.
• Capacity Expansion: To meet surging demand, the new Zhubei facility is slated for production this year, bringing total capacity to serve over 100,000 patients. Additionally, the company is investing US$46 million to establish a subsidiary and manufacturing site in Puerto Rico. This "Taiwan-US Dual-Base" strategy aims to mitigate supply chain risks and lower manufacturing costs by 2027.
• Pipeline Catalysts: Approvals for Essential Thrombocythemia (ET) are expected in the US, Japan, Taiwan, and China in 2026. Following a recent filing in South Korea, PharmaEssentia is positioned for a five-country synchronized launch in the ET segment.

Resource: 營運大豐收！藥華藥去年EPS 13.64元 配發每股2.6元股利 同步創高